Subset analysis for the associations between clinical features and immune-related adverse events (IRAEs): grade 3–5 IRAEs versus no IRAEs
| OR (90% CI) | p-value | |
| FV: positive versus negative (reference) | 0.46 (0.26–0.84) | 0.016* |
| Race: White versus non-White (reference) | 2.70 (0.79–9.25) | 0.092 |
| Gender: male versus female (reference) | 0.89 (0.48–1.67) | 0.382 |
| Smoking status: ever versus never (reference) | 4.97 (0.82–30.18) | 0.072 |
| Age: <60 versus ≥60 years (reference) | 0.86 (0.43–1.72) | 0.357 |
| Trial: yes versus no (reference) | 0.94 (0.48–1.85) | 0.439 |
| ICI received: | ||
| PD-L1 versus PD-1 (reference) | 2.80 (0.91–8.61) | 0.065 |
| CTLA-4/CTLA-4 combinations versus PD-1 (reference) | 2.95 (1.13–7.72) | 0.032* |
FV: influenza vaccination; ICI: immune checkpoint inhibitor; PD-L1: PD-1 ligand 1; PD-1: programmed cell death 1; CTLA-4: cytotoxic T-lymphocyte antigen 4. Harrell's C-statistic=0.691. *: p<0.05.